Corvus Pharmaceuticals, Inc. $CRVS Shares Acquired by Towerview LLC

Towerview LLC increased its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 33.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,000 shares of the company’s stock after acquiring an additional 42,500 shares during the period. Corvus Pharmaceuticals makes up about 0.5% of Towerview LLC’s investment portfolio, making the stock its 15th largest position. Towerview LLC’s holdings in Corvus Pharmaceuticals were worth $680,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of CRVS. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth approximately $672,000. Masso Torrence Wealth Management Inc. lifted its stake in Corvus Pharmaceuticals by 42.9% during the second quarter. Masso Torrence Wealth Management Inc. now owns 50,000 shares of the company’s stock valued at $200,000 after purchasing an additional 15,000 shares during the last quarter. OMERS ADMINISTRATION Corp grew its position in Corvus Pharmaceuticals by 9.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 82,300 shares of the company’s stock worth $262,000 after buying an additional 6,800 shares during the last quarter. Jump Financial LLC purchased a new position in Corvus Pharmaceuticals during the 1st quarter worth approximately $143,000. Finally, Wellington Management Group LLP purchased a new position in Corvus Pharmaceuticals during the 1st quarter valued at about $333,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CRVS shares. Wall Street Zen lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 18th. Barclays initiated coverage on shares of Corvus Pharmaceuticals in a report on Monday, October 13th. They issued an “overweight” rating and a $16.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, October 8th. Finally, Mizuho set a $13.00 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.25.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $7.82 on Friday. The company has a 50 day moving average of $6.81 and a 200-day moving average of $5.07. Corvus Pharmaceuticals, Inc. has a one year low of $2.54 and a one year high of $10.00. The stock has a market cap of $584.00 million, a price-to-earnings ratio of -14.75 and a beta of 0.56.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Tuesday, November 4th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Equities research analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.